Journal Article Summary
The article investigates the clinical characteristics of High-Impact Chronic Pain (HICP) in children with sickle cell disease (SCD) during consultations for hematopoietic cell transplant (HCT). Understanding HICP is crucial because it significantly affects patients' quality of life and can lead to increased healthcare utilization and poor health outcomes. By identifying the phenotype of HICP in this population, healthcare providers can better recognize those at risk for severe pain and disability, which may prompt earlier and more effective interventions.
In this retrospective study, researchers analyzed electronic health records of 46 children with SCD diagnosed with HICP during HCT consultations. The average age of participants was 14.5 years, with a majority having a severe genotype of SCD. The findings revealed that many of these children experienced frequent healthcare visits for pain, with a median of six visits in the year leading up to the consultation. Additionally, a significant number were prescribed disease-modifying medications and adjuvant analgesics, indicating a high burden of pain management needs.
Despite its valuable insights, the study has limitations, including a small sample size and potential biases due to the specific population of children attending HCT consultations. Not all individuals with HICP may seek or be referred for HCT, which could affect the generalizability of the findings. Patients and caregivers should discuss the implications of chronic pain and HICP with healthcare professionals, as early identification and intervention may improve outcomes and quality of life for those affected by SCD.
Medication Safety Note
This journal article summary is provided for educational purposes only and is not medical advice. Always consult a licensed healthcare professional before starting, stopping, or changing any medication.
Article Cited
- Huang Serena, Gillespie Scott, Chou Eric, Liu Katie, Jagtiani Ashna, Krishnamurti Lakshmanan, Bakshi Nitya. Clinical phenotype of high-impact chronic pain in sickle cell disease at consultation for hematopoietic cell transplant. Journal of Sickle Cell Disease 2025. DOI: 10.1093/jscdis/yoaf028. PMID: 41024866. PMCID: PMC12476911.
Featured Pill Pals Product
Methocarbamol 500 mg Tablets --- Generic For Robaxin --- Granules
Methocarbamol 500 mg Tablets — Generic For Robaxin — Granules is available through Pill Pals Pharmacy with cash-pay pharmacy pricing and free shipping where available. Prescription required.
Request a prescription transfer and our pharmacy team will help coordinate the next step.
